Navigation Links
Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
Date:4/1/2009

LOS ANGELES and TAMPA, Fla., April 1 /PRNewswire/ -- Stem Cell Biotherapy ("SCB") announced that it filed a lawsuit today in Los Angeles County Superior Court against the Company's Co-Founder and former President Casey Nabavi of Calabasas, California, for among other things conduct by Nabavi giving rise to patient claims against Nabavi that he had misrepresented himself as a medical doctor, practiced medicine without a license, supervised the injection of stem cells which caused some patients to become ill and personally advised patients how to manage these side effects. Nabavi/Cellulogix have offices/clinics in Los Angeles, Tampa, Montreal, Zona Rio (Mexico) and Istanbul.

The SCB lawsuit also seeks to recover SCB funds in excess of $1.65 million that Navabi paid himself before leaving SCB, to recover assets including intellectual property belonging to SCB which Navabi took and used to start-up the new Cellulogix business, to prevent Nabavi from continuing to compete with SCB in contravention of the parties' non-competition agreement and for SCB to recover ownership, the business and profits of Cellulogix as belonging to SCB not to Navabi as a result of Nabavi's wrongful conduct and activities. A copy of the SCB lawsuit against Nabavi and Cellulogix can be viewed at the Company's web site www.stemcellbiotherapy.com at "Recent News".

SCB is in the business of assisting persons who desire to try stem cell therapy treatment for serious medical problems which have not responded to traditional medical treatments. SCB uses medical clinics and specialized doctors in locations around the world where stem cell therapy is authorized to treat medical conditions such as spinal cord injury, ALS, Parkinsonism, Alzheimer's, multiple sclerosis, autism, cerebral palsy, brain damage, heart disease, COPD, kidney diseases, eye diseases, diabetes, transverse myelitis, etc.
'/>"/>

SOURCE Stem Cell Biotherapy
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. A potential molecular target for biotherapy esophageal squamous cell carcinomas
2. IntegriChain Enlists Ed Casey and Associates to Drive Counterfeit and Diversion Monitoring Service
3. The National Association for Home Care & Hospice (NAHC) Joins Sens. Susan Collins and Bob Casey and Reps. Jim McGovern and Walter Jones in Urging Access to Home Health Care
4. Casey Family Programs Hires Ken Patterson as Managing Director of Child and Family Services
5. Casey Family Programs Appoints Dr. America Bracho as New Board Member
6. Casey Family Programs Appoints New Board Members
7. Casey Family Programs Names Alabamas Walley Managing Director for Strategic Consulting
8. Columbus Medicare Diabetes Screening Project Cited as Model for State by Lt. Governor Casey Cagle
9. GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
10. Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation
11. Statement by Steve Case, Co-Founder, AOL and Chairman of Accelerate Brain Cancer Cure (www.ABC2.org) on News of Senator Ted Kennedys Brain Cancer Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... 2015 Could genetic code determine someone’s ... study by researchers at the Harvard T.H. Chan ... support of the Coffee and Caffeine Genetics Consortium and ... past fall, the study—one of several recent HSPH investigations ... from more than 120,000 regular coffee drinkers of European ...
(Date:3/28/2015)... 2015 Thousands of transvaginal mesh ... C.R. Bard, Inc. continue to move forward in ... Southern District of West Virginia, where Bernstein Liebhard ... Plaintiffs’ Steering Committee. According to an Order ... defendants named in those lawsuits leave to amend ...
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... highlighted a problem which could prove critical to organizations ... system testing, a critical aspect of data security, is ... card industry data security report, every major category out ... scanning and penetration testing. “With all the craziness that ...
(Date:3/28/2015)... 2015 How best to treat and ... in orthopaedic medicine. While diagnostic hip injections are commonly ... pain etiology, research presented today at the American Orthopaedic ... suggests that pain relief from this diagnostic injection may ... , “Our study looked to assess if the amount ...
(Date:3/28/2015)... March 28, 2015 Andrew Hawley of Vintage ... Who psychedelic concert posters. The Who and the Doors played ... August 2, 1968. According to Hawley, “The Who toured the ... halls and college campuses. Perhaps the most famous Who poster ... Morrison and the Doors on August 2, 1968 at the ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2
... Age should not be a factor in determining ... shown that older heart transplant patients do just as ... evaluated all 275 adult patients who received a heart ... and 2000. The patients' mortality and morbidity rates were ...
... and people without liver cancer found that diabetics are stand ... the general population.// ,After taking other factors into account, ... researchers found diabetes nearly tripled the risk of liver cancer. ... for liver cancer, may be boosting the risk even further. ...
... cause skin cancer – melanoma ,however researchers as the number ... number of patients surviving the disease. // Two new studies ... kinds of cancer. In a study conducted by researchers on ... it was discovered that melanoma patients with higher levels of ...
... The most deadly form of skin cancer , advanced ... with tumor proteins, say researchers according to a recent ... with tumor antigens (called MAGE-3) might have on patients’ ... was found that injecting patients with the tumor antigens ...
... a recent study researchers focused on the use ... their impact on cholesterol and C-reactive protein levels. ... the liver that predicts inflammation in the arteries. ... important key to determining cardiovascular risk.,Researchers focused on ...
... the heart's own can, such as raising the heart rate ... a hill but researchers say a pacemaker created by // ... have shown that genetically engineered heart cells from human embryonic ... according to a new study. Researchers injected clusters of human ...
Cached Medicine News:
(Date:3/27/2015)... Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending ... as the country,s manufacturing leader in innovation and economic ... to the  analysis , the industry had the highest ... accounting for 27 percent of average annual R&D spending ... on Medicare Part D - Medicare Part D ...
(Date:3/27/2015)... 2015 The Temple Health & Bioscience District (THBD) ... building at 1802 South First St. in the Temple Medical ... City of Temple to receive funding ... Central Texas Veterans Health Care System, the new facility will ... stage biotechnology and life science companies. ...
(Date:3/27/2015)... A new report from Kalorama Information says that other countries ... Chile , Colombia and ... The healthcare research firm said that while Brazil ... American continent with a population of over 200 million people ... country,s regional economic clout does not necessarily ensure its status ...
Breaking Medicine Technology:Week in Review: The Latest from PhRMA 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
... May 2, 2012 Zogenix, Inc. (NASDAQ: ... for the treatment of central nervous system disorders and ... New Drug Application (NDA) to the U.S. Food and ... Zogenix,s lead investigational product candidate for the treatment of ...
... 2012 Oxford BioTherapeutics (OBT) today announces ... Officer (COO) of the OBT group. In this position ... operations based in Basel, Switzerland.  The establishment of a ... global expansion as it progresses its most advanced therapeutic ...
Cached Medicine Technology:Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 2Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 3Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 4Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 5Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 6Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland 2Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland 3
... Plus Retics is a 5-part differential control ... the Abbott CELL-DYN 3200, 3500, 3700 and ... contains nucleated red blood cells that can ... 4000. The assay contains automated and manual ...
... Sickle-Chex is a positive and negative whole ... of Hemoglobin S in solubility tests and ... SICKLEDEX and other manufacturers' solubility kits. ... squeeze dropper vial. The vial dispenses an ...
... blood hematology control manufactured specifically for the ... the Coulter AcT5diff instruments. The composition of ... differential, positioning the populations within the limitations ... product offers 105-day closed-vial stability and 14-day ...
... STaK-Chex, a whole blood assayed hematology ... five-part white cell differential available with the ... unique product has 14-day open-vial stability, 105-day ... normal and high levels. The 4.0ml pierceable ...
Medicine Products: